Literature DB >> 31808420

Fly model sheds light on brain disease.

Martin H Berryer1,2, Sara G Kosmaczewski1,2, Lindy E Barrett1,2.   

Abstract

Experiments on flies suggest that a gain-of-function mechanism in a protein called CSPɑ contributes to the progressive brain disease CLN4.
© 2019, Berryer et al.

Entities:  

Keywords:  D. melanogaster; cysteine-string protein; lysosome; neurodegeneration; neuronal ceroid lipofuscinosis; neuroscience

Mesh:

Year:  2019        PMID: 31808420      PMCID: PMC6897533          DOI: 10.7554/eLife.53233

Source DB:  PubMed          Journal:  Elife        ISSN: 2050-084X            Impact factor:   8.140


Related research article Imler E, Pyon JS, Kindelay S, Torvund M, Zhang YQ, Chandra SS, Zinsmaier KE. 2019. A Drosophila model of neuronal ceroid lipofuscinosis CLN4 reveals a hypermorphic gain of function mechanism. eLife 8:e46607. doi: 10.7554/eLife.46607 Neuronal ceroid lipofuscinosis (NCL) refers to a group of progressive brain diseases that affect between 1 and 30 per 100,000 people and are characterized by a decline in motor abilities, seizures, dementia and premature death (Nosková et al., 2011; Haltia, 2003). Most NCLs are caused by the failure of cells to recycle various proteins inside lysosomes (Wisniewski et al., 2001; Henderson et al., 2016; Sambri et al., 2017; Warrier et al., 2013). However, one type of neuronal ceroid lipofuscinosis is different: CLN4 disease occurs when a patient inherits one mutant copy of the gene that encodes for a protein called CSPɑ, but the precise cellular dysfunction underlying CLN4 disease remains a mystery (Nosková et al., 2011; Benitez and Sands, 2017). Mutations in this gene have been associated with both loss and gain of function. In theory, the mutations could deplete normal CSPɑ, and this loss of function could contribute to disease pathology. Alternatively, the mutations could enhance the normal activity of CSPɑ or lead to an additional, toxic function to drive disease pathology. Now, in eLife, Konrad Zinsmaier and colleagues at the University of Arizona and Yale University – including Elliot Imler as first author – report the generation of a new animal model to investigate the biological mechanisms underlying CLN4 disease (Imler et al., 2019). Imler et al. started by expressing either the normal or mutant human forms of CSPɑ in flies and confirming that both were functional in fly cells. Next they confirmed that mutant forms of CSPɑ could mimic pathological features seen in CLN4 patients. Interestingly, they found that the severity of the disease correlated with the copy number of the mutated gene: a single copy of the mutated gene did not affect lifespan, but two copies led to more severe phenotypes and early death. To confirm that these results were not an artifact of expressing a human protein in flies, Imler et al. repeated many of their experiments using mutant versions of fly CSPɑ. The Arizona–Yale team then looked at where mutant CSPɑ resides in neurons. Normally, one would expect to find CSPɑ at nerve terminals, but the mutations resulted in lower levels of the protein at nerve terminals and higher levels in regions of the cell that contained other proteins that had been marked for degradation. By using markers of different cellular components, the researchers demonstrated that mutant CSPɑ was accumulating on prelysosomal endosomes. An endosome is a mini-compartment within a cell that internalizes molecules from the cell membrane: the endosome then fuses with an organelle called a lysosome, and the molecules inside it are broken down and recycled. Imler et al. hypothesize that mutant CSPɑ may be re-routed from nerve terminals through the endolysosomal pathway. Consistent with this, electron microscopy revealed the formation of abnormal membrane structures in cells, which may be due to mutant CSPɑ congesting the trafficking system. Next, Imler et al. modulated the levels of normal and mutant CSPɑ in cells. Reducing the level of normal CSPɑ reduced the mutant phenotypes, while increasing it exacerbated the mutant phenotypes. Similarly, reducing the level of a heat shock protein that normally interacts with CSPɑ attenuated mutant phenotypes, suggesting that the heat shock protein may play a role in disease biology. The Arizona–Yale team suggests that the disease-causing mutations in CSPɑ enhance its normal activity to disrupt the function of neurons. This gain-of-function mechanism is distinct from that found in the other NCLs, which typically arise from a deficiency in the function of the mutated gene. The results of Imler et al. demonstrate the value of the fruit fly model to study CLN4 disease pathology. However, these results also paint a complex picture of CLN4, and much work remains to be done to understand how each molecular or cellular pathology contributes to the devastating cognitive and motor deficits found in patients. Future work can now focus on how these biochemical disruptions impact neuronal function over time, taking advantage of the many tools and techniques available in fly genetics in order to interrogate pathways that have additive or compensatory mechanisms that may someday yield therapeutic potential.
  8 in total

Review 1.  The neuronal ceroid-lipofuscinoses.

Authors:  Matti Haltia
Journal:  J Neuropathol Exp Neurol       Date:  2003-01       Impact factor: 3.685

Review 2.  Genetic basis and phenotypic correlations of the neuronal ceroid lipofusinoses.

Authors:  Varun Warrier; Mariana Vieira; Sara E Mole
Journal:  Biochim Biophys Acta       Date:  2013-03-28

3.  Mutations in DNAJC5, encoding cysteine-string protein alpha, cause autosomal-dominant adult-onset neuronal ceroid lipofuscinosis.

Authors:  Lenka Nosková; Viktor Stránecký; Hana Hartmannová; Anna Přistoupilová; Veronika Barešová; Robert Ivánek; Helena Hůlková; Helena Jahnová; Julie van der Zee; John F Staropoli; Katherine B Sims; Jaana Tyynelä; Christine Van Broeckhoven; Peter C G Nijssen; Sara E Mole; Milan Elleder; Stanislav Kmoch
Journal:  Am J Hum Genet       Date:  2011-08-04       Impact factor: 11.025

Review 4.  Pheno/genotypic correlations of neuronal ceroid lipofuscinoses.

Authors:  K E Wisniewski; N Zhong; M Philippart
Journal:  Neurology       Date:  2001-08-28       Impact factor: 9.910

5.  Neuronal ceroid lipofuscinosis with DNAJC5/CSPα mutation has PPT1 pathology and exhibit aberrant protein palmitoylation.

Authors:  Michael X Henderson; Gregory S Wirak; Yong-Quan Zhang; Feng Dai; Stephen D Ginsberg; Natalia Dolzhanskaya; John F Staropoli; Peter C G Nijssen; TuKiet T Lam; Amy F Roth; Nicholas G Davis; Glyn Dawson; Milen Velinov; Sreeganga S Chandra
Journal:  Acta Neuropathol       Date:  2015-12-10       Impact factor: 17.088

6.  Primary fibroblasts from CSPα mutation carriers recapitulate hallmarks of the adult onset neuronal ceroid lipofuscinosis.

Authors:  Bruno A Benitez; Mark S Sands
Journal:  Sci Rep       Date:  2017-07-24       Impact factor: 4.379

7.  Lysosomal dysfunction disrupts presynaptic maintenance and restoration of presynaptic function prevents neurodegeneration in lysosomal storage diseases.

Authors:  Irene Sambri; Rosa D'Alessio; Yulia Ezhova; Teresa Giuliano; Nicolina Cristina Sorrentino; Vincenzo Cacace; Maria De Risi; Mauro Cataldi; Lucio Annunziato; Elvira De Leonibus; Alessandro Fraldi
Journal:  EMBO Mol Med       Date:  2017-01       Impact factor: 12.137

8.  A Drosophila model of neuronal ceroid lipofuscinosis CLN4 reveals a hypermorphic gain of function mechanism.

Authors:  Elliot Imler; Jin Sang Pyon; Selina Kindelay; Meaghan Torvund; Yong-Quan Zhang; Sreeganga S Chandra; Konrad E Zinsmaier
Journal:  Elife       Date:  2019-10-30       Impact factor: 8.140

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.